Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pimecrolimus topical - Novartis/Meda

Drug Profile

Pimecrolimus topical - Novartis/Meda

Alternative Names: ASM 981; Douglan; Elidel; Pimecrolimus cream; SDZ ASM 981; Topical pimecrolimus - Novartis

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Antipsoriatics; Macrolides
  • Mechanism of Action Calcineurin inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis
  • No development reported Dry eyes; Seborrhoeic dermatitis; Vitiligo
  • Discontinued Psoriasis

Most Recent Events

  • 09 Jul 2019 No development reported - Phase-III for Atopic dermatitis (In adolescents, In children) in Japan (Topical) (NDR batch #16)
  • 09 Jul 2019 No development reported - Phase-III for Atopic dermatitis (In adults) in Japan (Topical) (NDR batch #16)
  • 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top